Subgroup analysis of our findings showed that trial duration, intervention dose, and BMI status significantly affect the insulin level, as well as, it was shown that trial duration, intervention dose, obesity, and health status have a significant effect on the HOMA-IR levels. The gene discussed is INS; the disease is Obesity.